Argos Therapeutics Completes Enrollment in Cancer Study - Analyst Blog
Argos Therapeutics, Inc. ARGS announced that the pivotal phase III ADAPT study on its most advanced candidate AGS-003 has reached its enrollment goal of at least 450 randomized patients. The study will evaluate the use of AGS-003, an autologous dendritic-cell based immunotherapy, in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma (mRCC).
The ADAPT study is being conducted under the FDA’s special protocol assessment. The company plans to conduct interim data review from the study in the first part of 2016.
As per data from the International mRCC Database Consortium (IMDC), median survival benchmark is approximately only 15 months post diagnosis, indicating significant unmet need despite use of standard surgery and currently approved targeted therapies.
We believe that AGS-003 holds the potential to address this need and provide a treatment option to patients suffering from mRCC. Earlier, in an open-label phase II study, AGS-003 in combination with Pfizer Inc.’s PFE Sutent (sunitinib) showed a median overall survival of more than 30 months in newly diagnosed, unfavorable risk mRCC patients. We expect investor focus to remain on pipeline updates from the company.
Argos Therapeutics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Eleven Biotherapeutics, Inc. EBIO and Anacor Pharmaceuticals, Inc. ANAC. While Eleven Biotherapeutics carries a Zacks Rank #1 (Strong Buy), Anacor holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
ANACOR PHARMACT (ANAC): Free Stock Analysis Report
ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report
ARGOS THERAPEUT (ARGS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
